AR039843A1 - Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama - Google Patents

Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama

Info

Publication number
AR039843A1
AR039843A1 ARP030101779A ARP030101779A AR039843A1 AR 039843 A1 AR039843 A1 AR 039843A1 AR P030101779 A ARP030101779 A AR P030101779A AR P030101779 A ARP030101779 A AR P030101779A AR 039843 A1 AR039843 A1 AR 039843A1
Authority
AR
Argentina
Prior art keywords
patients
breast
cancer
menopausic
post
Prior art date
Application number
ARP030101779A
Other languages
English (en)
Inventor
Helenius Jan Kloosterboer
Anton Egbert Peter Adang
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of AR039843A1 publication Critical patent/AR039843A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Uso de tibolona y un SERM para fabricar una medicina para tratar una deficiencia de estrógeno relacionada con la enfermedad y para la prevención de una recurrencia de cáncer de mamas en las mujeres que sufren de cáncer de mama o que están en riesgo de ello que exhiben la deficiencia de estrógeno relacionada con la enfermedad. Reivindicación 2: Un uso de acuerdo a la reivindicación 1, caracterizado porque el SERM es tamoxifén. Reivindicación 3: Un uso de acuerdo a la reivindicación 1, caracterizado porque el SERM es raloxifeno.
ARP030101779A 2002-05-24 2003-05-22 Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama AR039843A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02077050 2002-05-24

Publications (1)

Publication Number Publication Date
AR039843A1 true AR039843A1 (es) 2005-03-02

Family

ID=29558370

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101779A AR039843A1 (es) 2002-05-24 2003-05-22 Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama

Country Status (14)

Country Link
US (1) US20050222100A1 (es)
EP (1) EP1511497A1 (es)
JP (1) JP2005531575A (es)
KR (1) KR20050005490A (es)
CN (1) CN1655796A (es)
AR (1) AR039843A1 (es)
AU (1) AU2003273170A1 (es)
BR (1) BR0311146A (es)
CA (1) CA2487268A1 (es)
IL (1) IL165129A0 (es)
MX (1) MXPA04011687A (es)
PE (1) PE20031047A1 (es)
TW (1) TW200307553A (es)
WO (1) WO2003099292A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0862445B2 (en) * 1995-10-06 2017-03-22 Arch Development Corporation Combination of herpes simplex virus and chemotherapy for treating cancer
WO2007143607A2 (en) 2006-06-02 2007-12-13 Pear Tree Women's Health Care Method of treating atrophic vaginitis
US8933130B2 (en) 2006-06-23 2015-01-13 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
WO2009137104A1 (en) * 2008-05-09 2009-11-12 Radius Health, Inc. Combination therapy for breastcancer comprising an antiestrogenic agent
DE102008057230A1 (de) * 2008-11-11 2010-05-12 Bayer Schering Pharma Aktiengesellschaft Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin
ME02474B (me) 2010-05-12 2017-02-20 Radius Health Inc Terapijski režimi
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
ES2939940T3 (es) 2014-03-28 2023-04-28 Univ Duke Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
RU2737496C2 (ru) 2015-04-29 2020-12-01 Радиус Фармасьютикалз, Инк. Способы лечения рака
JP7221699B2 (ja) 2016-06-22 2023-02-14 エリプセス ファーマ エルティーディー Ar+乳癌の治療方法
FI3565542T3 (fi) 2017-01-05 2024-06-24 Radius Pharmaceuticals Inc Rad1901-2hcl:n polymorfisia muotoja
US11643385B2 (en) 2018-07-04 2023-05-09 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD1901-2HCl

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2342145C2 (ru) * 2000-01-28 2008-12-27 Андорешерш, Инк. Селективные модуляторы рецептора эстрогена в комбинации с эстрогенами
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
HUP0401268A2 (hu) * 2001-07-31 2004-11-29 Pfizer Products Inc. Ösztrogén agonisták/antagonisták, ösztrogének és progesztinek kombinációját tartalmazó gyógyszerkészítmények, valamint eljárás ezek előállítására

Also Published As

Publication number Publication date
KR20050005490A (ko) 2005-01-13
MXPA04011687A (es) 2005-03-31
WO2003099292A1 (en) 2003-12-04
EP1511497A1 (en) 2005-03-09
CA2487268A1 (en) 2003-12-04
JP2005531575A (ja) 2005-10-20
US20050222100A1 (en) 2005-10-06
TW200307553A (en) 2003-12-16
CN1655796A (zh) 2005-08-17
AU2003273170A1 (en) 2003-12-12
PE20031047A1 (es) 2003-12-23
IL165129A0 (en) 2005-12-18
BR0311146A (pt) 2005-03-15

Similar Documents

Publication Publication Date Title
AR039843A1 (es) Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama
ECSP045069A (es) Uso de flibanserina en el tratamiento de trastornos sexuales
DOP2002000429A (es) Imidazotriazinas
DE60143857D1 (de) Zusammensetzung bestehend aus phy906 und chemotherapeutika
BRPI0608815A8 (pt) Composições de anticorpo anti-ctla-4
BRPI0407234A (pt) Heterociclos substituìdos
AR033555A1 (es) Producto para el tratamiento del carcinoma de receptor de estrogeno positivo, y uso de dicho producto para preparar medicamentos
UY27939A1 (es) Compuestos
GT200300294A (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
CY1104981T1 (el) Χρηση των αντιπρογεστερονων για προληψη και αντιμετωπιση των εξαρτωμενων απο ορμονες ασθενειων
PA8513101A1 (es) Derivados de eteres de pirazol como agentes anti- inflamatorios/analgesicos
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
ATE445389T1 (de) Liposomale glucocorticoide
CY1108462T1 (el) Χρηση της αναστροζολης για τη θεραπευτικη αντιμετωπιση μετεμμηνοπαυσιακων γυναικων με καρκινο του μαστου σε πρωιμο σταδιο
BR0209645A (pt) Oxazolo- e furopirimidinas e seu uso como medicamentos
BR0010702A (pt) Novas quinonas como terapias de doenças
UY26992A1 (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinérgicos y corticoesteroides
AR037343A1 (es) Uso de antagonistas del receptor de endotelina para la preparacion de un medicamento destinado al tratamiento de enfermedades tumorales
SE0300098D0 (sv) Use of cyclin D1 inhibitors
BRPI0407611A (pt) agente anti-cáncer compreendendo proteìna lk8 como um ingrediente ativo
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
AR025718A1 (es) Metodo para reducir el riesgo de cancer
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
AR049195A1 (es) Uso de una combinacion de etinilestradiol y acetato de clormadinona para la preparacion de un medicamento

Legal Events

Date Code Title Description
FA Abandonment or withdrawal